JP2022553954A5 - - Google Patents
Info
- Publication number
- JP2022553954A5 JP2022553954A5 JP2022523564A JP2022523564A JP2022553954A5 JP 2022553954 A5 JP2022553954 A5 JP 2022553954A5 JP 2022523564 A JP2022523564 A JP 2022523564A JP 2022523564 A JP2022523564 A JP 2022523564A JP 2022553954 A5 JP2022553954 A5 JP 2022553954A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- formula
- therapeutically effective
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025120941A JP2025157436A (ja) | 2019-10-22 | 2025-07-18 | 前立腺癌を治療する方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962924655P | 2019-10-22 | 2019-10-22 | |
| US62/924,655 | 2019-10-22 | ||
| US201962945418P | 2019-12-09 | 2019-12-09 | |
| US62/945,418 | 2019-12-09 | ||
| US202063028843P | 2020-05-22 | 2020-05-22 | |
| US63/028,843 | 2020-05-22 | ||
| US202063032453P | 2020-05-29 | 2020-05-29 | |
| US63/032,453 | 2020-05-29 | ||
| PCT/US2020/056684 WO2021081108A1 (en) | 2019-10-22 | 2020-10-21 | Methods of treating prostate cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025120941A Division JP2025157436A (ja) | 2019-10-22 | 2025-07-18 | 前立腺癌を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022553954A JP2022553954A (ja) | 2022-12-27 |
| JP2022553954A5 true JP2022553954A5 (enExample) | 2023-10-20 |
| JP7716396B2 JP7716396B2 (ja) | 2025-07-31 |
Family
ID=73449188
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022523564A Active JP7716396B2 (ja) | 2019-10-22 | 2020-10-21 | 前立腺癌を治療する方法 |
| JP2025120941A Pending JP2025157436A (ja) | 2019-10-22 | 2025-07-18 | 前立腺癌を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025120941A Pending JP2025157436A (ja) | 2019-10-22 | 2025-07-18 | 前立腺癌を治療する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20210113557A1 (enExample) |
| EP (1) | EP4048236A1 (enExample) |
| JP (2) | JP7716396B2 (enExample) |
| KR (1) | KR20220087482A (enExample) |
| CN (1) | CN115135313A (enExample) |
| AU (1) | AU2020370150A1 (enExample) |
| CA (1) | CA3158411A1 (enExample) |
| IL (1) | IL292359A (enExample) |
| MX (1) | MX2022004808A (enExample) |
| WO (1) | WO2021081108A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| SI3526202T1 (sl) | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| CN115996918A (zh) | 2020-05-09 | 2023-04-21 | 阿尔维纳斯运营股份有限公司 | 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型 |
| WO2022048605A1 (zh) * | 2020-09-04 | 2022-03-10 | 南昌奥瑞药业有限公司 | 一种杂环化合物、其制备方法、中间体、组合物以及应用 |
| WO2022087125A1 (en) * | 2020-10-21 | 2022-04-28 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor protein |
| US20220184078A1 (en) * | 2020-12-11 | 2022-06-16 | Arvinas Operations, Inc. | Methods of treating prostate cancer |
| CN113620931B (zh) * | 2021-09-13 | 2023-06-09 | 中国海洋大学 | 一种雄激素受体抑制剂及其用途 |
| WO2023205481A1 (en) * | 2022-04-21 | 2023-10-26 | Arvinas Operations, Inc. | A combination for use in treating prostate cancer comprising arv-100 and abiraterone |
| WO2024233696A1 (en) * | 2023-05-09 | 2024-11-14 | Arvinas Operations, Inc. | Bavdegalutamide for treating prostate cancer without ar l702h mutation |
| AU2024392985A1 (en) | 2023-12-08 | 2026-06-04 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US20140255413A1 (en) * | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| TWI686212B (zh) * | 2013-03-15 | 2020-03-01 | 阿聯商太陽法瑪全球有限公司 | 醋酸阿比特龍配方 |
| WO2015114314A1 (en) * | 2014-01-28 | 2015-08-06 | Cipla Limited | Pharmaceutical composition comprising abiraterone |
| EP4649963A3 (en) * | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| RS59490B1 (sr) * | 2014-11-21 | 2019-12-31 | Biohaven Therapeutics Ltd | Sublingvalna formulacija riluzola |
| AU2017278314B2 (en) * | 2016-06-10 | 2022-06-30 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
| JOP20190067A1 (ar) * | 2016-09-30 | 2019-03-28 | Janssen Pharmaceutica Nv | طُرق تشخيص وعلاج سرطان البروستاتا النقيلي المقاوم للإخصاء والمقاوم أو الحساس لأبيراتيرون أسيتات-الهرمون القشري السكري |
| SI3526202T1 (sl) * | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
-
2020
- 2020-10-21 US US17/075,808 patent/US20210113557A1/en not_active Abandoned
- 2020-10-21 IL IL292359A patent/IL292359A/en unknown
- 2020-10-21 CN CN202080080511.2A patent/CN115135313A/zh active Pending
- 2020-10-21 WO PCT/US2020/056684 patent/WO2021081108A1/en not_active Ceased
- 2020-10-21 EP EP20807571.3A patent/EP4048236A1/en not_active Withdrawn
- 2020-10-21 AU AU2020370150A patent/AU2020370150A1/en not_active Abandoned
- 2020-10-21 JP JP2022523564A patent/JP7716396B2/ja active Active
- 2020-10-21 MX MX2022004808A patent/MX2022004808A/es unknown
- 2020-10-21 KR KR1020227016404A patent/KR20220087482A/ko not_active Ceased
- 2020-10-21 CA CA3158411A patent/CA3158411A1/en active Pending
-
2022
- 2022-12-21 US US18/085,869 patent/US20230128132A1/en not_active Abandoned
-
2025
- 2025-07-18 JP JP2025120941A patent/JP2025157436A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022546471A5 (enExample) | ||
| JP2025116875A5 (enExample) | ||
| IL178745A (en) | Use of 4- (amino) -2 (2, 6-dioxo (3-piperidyl)) -isoindoline -1, 3-discussion of preparation of a medical vaccine for the treatment of myeloma | |
| US12077554B2 (en) | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer | |
| KR20070014184A (ko) | 성기능 장애 치료용 신규 약제학적 조성물 ⅱ | |
| JP2019515884A5 (enExample) | ||
| JP2024520630A5 (enExample) | ||
| JP2017530175A5 (enExample) | ||
| JP2010540508A5 (enExample) | ||
| US11065240B2 (en) | Drug combinations to treat multiple myeloma | |
| JP2016534063A5 (enExample) | ||
| JP2024531188A5 (enExample) | ||
| JP2020533283A5 (enExample) | ||
| JP2017522304A5 (enExample) | ||
| EP2124930B1 (en) | Isosorbide mononitrate derivatives for the treatment of intestinal disorders | |
| JP2025118775A5 (enExample) | ||
| JP7854206B2 (ja) | 肺線維症の予防または治療用の薬学製剤 | |
| JP2025509278A5 (enExample) | ||
| JP2022518288A5 (enExample) | ||
| CN113200966A (zh) | 一种呋喹替尼衍生物、药物组合物和用途 | |
| JP7788550B2 (ja) | ターフェニル化合物の安息香酸塩の製造方法 | |
| EP0623346A1 (en) | Inhibitor for metastasis of malignant tumor | |
| JP7150862B2 (ja) | アミノピラン誘導体の組成物 | |
| JP2024541770A5 (enExample) | ||
| TW202408499A (zh) | 降低血中肌肉生長抑制素之藥劑 |